


**Product Name** : OBX02-011  
**Cat. No.** : PC-47006  
**CAS No.** : 2349336-18-9  
**Molecular Formula** : C<sub>29</sub>H<sub>39</sub>ClN<sub>8</sub>O<sub>3</sub>S  
**Molecular Weight** : 615.194  
**Target** : EGFR  
**Solubility** : 10 mM in DMSO



## Biological Activity

OBX02-011 is a potent, reversible, fourth-generation **EGFR** tyrosine kinase inhibitor (TKI) that overcomes the EGFR C797S mutation, inhibits triple mutants Del19/T790M/C797S and L858R/T790M/C797S with IC<sub>50</sub> of 0.134 and 2.09 nM, respectively. OBX02-011 occupied the ATP-binding site in a similar manner to WZ-4002.

OBX02-011 showed broad activity at low nanomolar concentrations against mutant EGFRs, more potent in Del19/T790M/C797S and L858R/T790M than in other EGFR mutations.

OBX02-011 was highly effective against EGFR triple mutations, and showed substantial selectivity compared with WT EGFR (IC<sub>50</sub>= 1471 nM in WT, 96.3 nM in Del19/T790M/C797S, and 94.8 nM in L858R/T790M/C797S) in Ba/F3 cell lines expressing EGFR.

OBX02-011 (25 mg/kg, i. p.) effectively inhibited tumor growth and EGFR activity, leading to enhanced survival in transgenic mouse models (EGFRL858R/T790M/C797S).

## References

Yun Jung Choi, et al. *Cancer Res.* 2022 Jun 14;canres.0394.2022-2-3 21:03:12.200.

**Caution: Product has not been fully validated for medical applications. Lab Use Only!**

E-mail: tech@probechem.com